Natrecor Side Effects
Generic name: nesiritide
Note: This document contains side effect information about nesiritide. Some of the dosage forms listed on this page may not apply to the brand name Natrecor.
Some side effects of Natrecor may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to nesiritide: intravenous powder for solution
Along with its needed effects, nesiritide (the active ingredient contained in Natrecor) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking nesiritide:More common
- Low blood pressure
- Bluish lips or skin
- chest pain, tightness, or discomfort
- cool, clammy skin
- difficulty in breathing or shortness of breath
- fast, slow, or irregular heartbeat
- unusual tiredness or weakness
Some side effects of nesiritide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Abdominal or stomach pain
- back pain
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings on the skin
- change in vision
- coughing or spitting up blood
- increased cough
- itching skin
- leg cramps
- pain or irritation at the injection site
- pale skin, unusual bleeding or bruising
- sleepiness or unusual drowsiness
- trembling or shakiness
For Healthcare Professionals
Applies to nesiritide: intravenous powder for injection
Cardiovascular side effects have included hypotension (11% to 35%), ventricular tachycardia (3% to 10%), ventricular extrasystoles (3% to 4%), angina pectoris (2% to 6%), and bradycardia (1% to 5%). Other side effects occurring in at least 1% of patients have included tachycardia, atrial fibrillation, and AV node conduction abnormalities.
The mean duration of symptomatic hypotension was 2.2 hours with nesiritide, compared to 0.7 hours with nitroglycerin.
Nesiritide was associated with a lower incidence of severe ventricular arrhythmias than dobutamine: sustained ventricular tachycardia (1% vs 7%), nonsustained ventricular tachycardia (11% vs 17%), cardiac arrest (0 vs 5%).
Nervous system side effects have included headache (up to 4.2%), insomnia (2% to 6%), dizziness (3% to 6%), and anxiety (2% to 3%). Other side effects occurring in at least 1% of patients have included confusion, paresthesia, somnolence, tremor, and fever.
Gastrointestinal side effects have included dry mouth (up to 20.1%), constipation (up to 9.6%), upper abdominal pain (up to 1.5%), constipation (up to 1.4%), dyspepsia (up to 1.2%), and flatulence (up to 1.2%).
Local reactions reported in at least 1% of patients have included catheter pain and injection site reactions.
Respiratory side effects reported in at least 1% of patients have included increased cough and apnea.
Renal side effects reported have included increases in serum creatinine of greater than 0.5 mg/dL above baseline (17% in patients receiving 0.015 mcg/kg/min, 19% in patients receiving 0.03 mcg/kg/min, 28% in patients receiving a 2 mcg/kg bolus followed by 0.020 mcg/kg/min).
Other side effects have included anticholinergic central nervous system (CNS) effects including dizziness, confusion, hallucinations and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.
Ocular side effects have included amblyopia (up to 1%) and dry eyes (up to 1.2%).
Dermatologic side effects have included pruritus and rash in at least 1% of patients. Angioedema of the face, lips, tongue, and/or larynx has been reported postmarketing.
Endocrine side effects have included sweating in at least 1% of patients.
Musculoskeletal side effects have included back pain (1% to 4%) and leg cramps (at least 1%).
Hematologic side effects have included anemia in at least 1% of patients.
Metabolic side effects have included hypokalemia (3%) and hypomagnesemia (1% to 3%) in a trial with 103 CHF patients.
Hypersensitivity side effects including postmarketing reports of hypersensitivity reactions have been reported.
Genitourinary side effects have included urinary retention (up to 1.2%).
More Natrecor resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.